Generics in China

December 2024 | 45 pages | ID: G4723B44126EN
MarketLine

Abstracts

Generics in China

Summary

Generics in China industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

• A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
• The Chinese generics market recorded revenues of $121.0 billion in 2023, representing a compound annual growth rate (CAGR) of 12.7% between 2018 and 2023.
• Market consumption volume increased with a CAGR of 0.5% between 2018 and 2023, to reach a total of 80.0% of total pharma volume in 2023.
• According to GlobalData, in 2023, the Chinese generics market grew by 7.4% annually due to the country’s mounting aging population. According to the World Bank, in 2023, the percentage of the population aged 65 years and above out of the total population in China reached 14.3% as compared to 13.7% in 2022.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in China
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume

Reasons to Buy

• What was the size of the China generics market by value in 2023?
• What will be the size of the China generics market in 2028?
• What factors are affecting the strength of competition in the China generics market?
• How has the market performed over the last five years?
• Who are the top competitors in China's generics market?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths and strategies of the leading players?

8 COMPANY PROFILES

8.1. CSPC Pharmaceutical Group Ltd
8.2. Sino Biopharmaceutical Ltd
8.3. Teva Pharmaceutical Industries Ltd
8.4. Viatris Inc
8.5. Hansoh Pharmaceutical Group Co Ltd

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine